News

Arctic Therapeutics ehf, an Icelandic drug development company, in collaboration with Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in treatments for retinitis pigmentosa

Boehringer Ingelheim and Sosei Group Corporation have recently announced a global collaboration and an exclusive option-to-license agreement. The primary goal of this partnership

Eilean Therapeutics LLC, a biopharmaceutical company focusing on discovering and developing small molecule inhibitors for hematologic and solid malignancies, has announced a significant milestone.

Regeneron Pharmaceuticals, Inc. recently made a significant announcement regarding pediatric healthcare. The U.S. Food & Drug Administration has extended the approval of Praluent®

Apex Labs Ltd., a pharmaceutical company at the forefront of mental health treatment using psilocybin, is excited to announce the submission of a provisional patent application to the United States Patent and Trademark Office

Mind Medicine Inc., a company specializing in the development of treatments for brain health disorders, has received a breakthrough designation from the FDA for its MM120 program aimed at treating generalized anxiety disorder

Ludwig Enterprises, Inc, a US-based biotechnology company, is excited to announce the successful filing of its provisional patent titled "mRNAs Differentially Expressed in Colorectal Cancer,

Mainz Biomed N.V, a leader in molecular genetics diagnostic solutions for early cancer detection, has announced a strategic collaboration with Trusted Health Advisors, a prominent player in supporting the launch and management

YolTech Therapeutics, a leading biotechnology company specializing in in vivo gene editing therapies for rare genetic diseases, has achieved a significant milestone with the approval of the YOLT-201 investigational new drug application by the Center for Drug Evaluation

Vivoryon Therapeutics N.V. recently disclosed the top-line findings from its Phase 2b European VIVIAD trial of varoglutamstat , an oral glutaminyl cyclase inhibitor being explored for early Alzheimer’s disease